A team of scientists in Germany believe that they have figured out why an increased number of individuals have experienced blood clots after receiving the AstraZeneca and Johnson & Johnson Covid-19 vaccines.
The scientists also believe that they can tell the manufacturers how to improve the vaccine itself to avoid clots. Rolf Marschalek, a professor at Goethe university in Frankfurt, and colleagues spoke with the media recently about their discovery.
“The key is in the adenovirus – the common cold virus that is used to deliver the spike protein of the coronavirus into the body. The mRNA vaccines developed by Pfizer/BioNTech and Moderna do not use this delivery system and there have been no blood clotting cases linked to them.”
The blood clots have been very rare, as with any vaccine, however, many parents are concerned about the younger age groups receiving their vaccines as there’s already less of a chance that they’ll develop severe Covid illness, but an increased risk that they would experience a blood clot.
Currently the UK is offering vaccines to anyone under the age of 40 wherever vaccines are available. There have been 309 blood clotting cases in the UK out of 33 million people given the AstraZeneca vaccine. The scientists in a preprint analysis claim that they believe the “problem lies in the entry of the adenovirus into the nucleus of the cell rather than just the cellular fluid, where the virus normally makes proteins.”
“The adenovirus life cycle includes the infection of cells entry of the adenoviral DNA into the nucleus, and subsequently gene transcription by the host transcription machinery. Here lies the problem: the viral piece of DNA is not optimised to be transcribed inside of the nucleus.”
Inside of the cell’s nucleus, parts of the spike protein splice, or split apart. These sliced pieces can then become mutant protein pieces that free float throughout your body, and lead to an increased risk of blood clots; although it’s extremely rare that that will occur.
Professor Marschalek claims that Johnson & Johnson are already in discussions with him, as he’s only continued to emphasize that “the vaccines can be redesigned to avoid the problem.”
“Johnson & Johnson is trying to optimize its vaccine now. With the data we have in our hands we can tell the companies how to mutate these sequences, coding for the spike protein in a way that prevents unintended splice reactions.”
No word on whether or not AstraZeneca has been contacted or not, and the research presented still needs to go through a peer review in order for it to gain more national credibility throughout the United Kingdom.
Eric Mastrota is a Contributing Editor at The National Digest based in New York. A graduate of SUNY New Paltz, he reports on world news, culture, and lifestyle. You can reach him at firstname.lastname@example.org.